Optima Pharma has, in the form of the INOVA SV, a well proven machine that had been re-engineered in recent years into a highly flexible modular system.
Optima Pharma has, in the form of the INOVA SV, a well proven machine that had been re-engineered in recent years into a highly flexible modular system.
The INOVA SV allows the processing of nested ready to use syringes, of nested vials and cartridges in one unit. Customers make a quick change within 30 minutes. The contact points of the system to the containers are reduced to an absolute minimum to allow for gentler processing. In addition, there is no glass to glass contact of any kind during the processing. A further factor concerns the filling systems. A number of variations are possible, all of which can be set up very quickly as part of the format change work: Rotary piston pumps, peristaltic pumps, mass flow metering and time-pressure systems offer advantages relative to the various types of pharmaceuticals. Additional modules and functions can be integrated, including filling under vacuum, pre- and post-flushing with gas, and up to 100% in-process control. Upstream, the pre-sterilized containers are manually to fully automatically unpacked and fed to the process. The post-processing section features such modules as backstop locks and safety devices, optical and sensor controls, labelers and track & trace systems. RAB systems and isolators can be deployed. A maximum output of 18,000 containers/hour is achieved via ten filling points, with a dosing range of 0.1 to 50 ml.
OPTIMA pharma GmbH
www.optima-pharma.com
E-mail: info@optima-pharma.com
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.